98 related articles for article (PubMed ID: 12587041)
21. Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats.
Yamaguchi H; Yano I; Saito H; Inui K
Pharm Res; 2004 Feb; 21(2):330-8. PubMed ID: 15032316
[TBL] [Abstract][Full Text] [Related]
22. p38 MAPK associated with stereoselective priming by grepafloxacin on O2- production in neutrophils.
Niwa M; Hotta K; Kanamori Y; Kumada M; Hirota M; Kozawa O; Fujimoto S
Free Radic Biol Med; 2004 May; 36(10):1259-69. PubMed ID: 15110391
[TBL] [Abstract][Full Text] [Related]
23. [Intracellular penetration of 5 quinolones into non-phagocytic cells].
García I; Pascual A; Conejo MC; Perea EJ
Enferm Infecc Microbiol Clin; 1996 Mar; 14(3):167-70. PubMed ID: 8695686
[TBL] [Abstract][Full Text] [Related]
24. Uptake of ciprofloxacin and ofloxacin by 2 Brucella strains and their fluoroquinolone-resistant variants under different conditions. An in vitro study.
Turkmani A; Psaroulaki A; Christidou A; Samoilis G; Mourad TA; Tabaa D; Tselentis Y
Diagn Microbiol Infect Dis; 2007 Dec; 59(4):447-51. PubMed ID: 17920802
[TBL] [Abstract][Full Text] [Related]
25. Transport characteristics of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2.
Yamaguchi H; Yano I; Saito H; Inui K
Eur J Pharmacol; 2001 Nov; 431(3):297-303. PubMed ID: 11730721
[TBL] [Abstract][Full Text] [Related]
26. Grepafloxacin pharmacokinetics in individuals with hepatic dysfunction.
Efthymiopoulos C; Bramer SL; Maroli A; Flaherty JF; Wolfe E; Bass N; Somberg K
Clin Pharmacokinet; 1997; 33 Suppl 1():25-31. PubMed ID: 9433653
[TBL] [Abstract][Full Text] [Related]
27. Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects.
Kozawa O; Uematsu T; Matsuno H; Niwa M; Nagashima S; Kanamaru M
Antimicrob Agents Chemother; 1996 Dec; 40(12):2824-8. PubMed ID: 9124849
[TBL] [Abstract][Full Text] [Related]
28. Transfer of ciprofloxacin, ofloxacin and levofloxacin across the perfused human placenta in vitro.
Polachek H; Holcberg G; Sapir G; Tsadkin-Tamir M; Polachek J; Katz M; Ben-Zvi Z
Eur J Obstet Gynecol Reprod Biol; 2005 Sep; 122(1):61-5. PubMed ID: 16154040
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin.
Child J; Andrews JM; Wise R
Antimicrob Agents Chemother; 1995 Feb; 39(2):513-5. PubMed ID: 7726523
[TBL] [Abstract][Full Text] [Related]
30. X-Ray crystallographic, NMR and antimicrobial activity studies of magnesium complexes of fluoroquinolones - racemic ofloxacin and its S-form, levofloxacin.
Drevensek P; Kosmrlj J; Giester G; Skauge T; Sletten E; Sepcić K; Turel I
J Inorg Biochem; 2006 Nov; 100(11):1755-63. PubMed ID: 16934331
[TBL] [Abstract][Full Text] [Related]
31. Induced and photoinduced DNA damage by quinolones: ciprofloxacin, ofloxacin and nalidixic acid determined by comet assay.
Sánchez G; Hidalgo ME; Vivanco JM; Escobar J
Photochem Photobiol; 2005; 81(4):819-22. PubMed ID: 15691228
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and ocular penetration of grepafloxacin in albino and pigmented rabbits.
Perez S; Solans C; Bregante MA; Pinilla I; García MA; Honrubia F
J Antimicrob Chemother; 2002 Oct; 50(4):541-5. PubMed ID: 12356799
[TBL] [Abstract][Full Text] [Related]
33. Entry of the new quinolone antibacterial agents of ofloxacin and NY-198 into the central nervous system in rats.
Sato H; Okezaki E; Yamamoto S; Nagata O; Kato H; Tsuji A
J Pharmacobiodyn; 1988 Jun; 11(6):386-94. PubMed ID: 3171880
[TBL] [Abstract][Full Text] [Related]
34. Factors influencing the intracellular activity of fluoroquinolones: a study using levofloxacin in a Staphylococcus aureus THP-1 monocyte model.
Nguyen HA; Grellet J; Paillard D; Dubois V; Quentin C; Saux MC
J Antimicrob Chemother; 2006 May; 57(5):883-90. PubMed ID: 16533826
[TBL] [Abstract][Full Text] [Related]
35. Safety profile of grepafloxacin compared with other fluoroquinolones.
Stahlmann R; Schwabe R
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():83-92. PubMed ID: 9484877
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of quinolones against S. pneumoniae, H. influenzae and M. catarrhalis in Saudi Arabia.
Balkhy HH; Memish ZA; Shibl A; Elbashier A; Osoba A
East Mediterr Health J; 2005; 11(1-2):36-44. PubMed ID: 16532669
[TBL] [Abstract][Full Text] [Related]
37. Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors.
Handa O; Yoshida N; Fujita N; Tanaka Y; Ueda M; Takagi T; Kokura S; Naito Y; Okanoue T; Yoshikawa T
Inflamm Res; 2006 Nov; 55(11):476-80. PubMed ID: 17122965
[TBL] [Abstract][Full Text] [Related]
38. Mechanism underlying levofloxacin uptake by human polymorphonuclear neutrophils.
Vazifeh D; Bryskier A; Labro MT
Antimicrob Agents Chemother; 1999 Feb; 43(2):246-52. PubMed ID: 9925513
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of Simian virus 40 large T antigen helicase activity by fluoroquinolones.
Ali SH; Chandraker A; DeCaprio JA
Antivir Ther; 2007; 12(1):1-6. PubMed ID: 17503741
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of ofloxacin penetration into the skin after a single oral dose assessed by cutaneous microdialysis.
Bielecka-Grzela S; Klimowicz A
Pol J Pharmacol; 2003; 55(4):613-8. PubMed ID: 14581720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
